期刊
JACC-CARDIOVASCULAR INTERVENTIONS
卷 3, 期 3, 页码 265-275出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2009.12.013
关键词
myocardial regeneration; stem cells; training; injection; catheter
资金
- Cardiovascular Biotherapeutics
- Angioblast Systems, Inc.
- Biologics Delivery Systems, Inc. (Cordis Corporation)
- Cardio3 Biosciences
- CardioPolymers Inc.
- Medtronic, Inc.
- Ablation Frontiers Inc.
- Astra-Zeneca Inc.
- Sanofi Aventis Inc.
- Magnetecs Inc.
- Bard Inc.
- Bioheart Inc.
- Lantheus
- Acusphere
- CV Therapeutics
- Philips Medical Systems
- General Electric Medical Systems
- Thoratec Corp
- Cordis Corporation
- Abbott Vascular
- Boston Scientific
- Cordis
- ev3
- [NIH-R01HL081715A1]
- [NIH-1R21DK078029-01]
- British Heart Foundation [RG/10/11/28457] Funding Source: researchfish
The field of myocardial regeneration (angiogenesis and myogenesis) might prove to play an important role in the future management of cardiovascular disease. Stem cells are currently undergoing testing in Phase I and Phase II clinical trials. Methods of delivery will affect the outcome of such therapies, perhaps significantly. This document provides suggested guidance in 4 methods of delivery: endocardial, intracoronary, coronary sinus, and epicardial. (J Am Coll Cardiol Inty 2010;3:265-75) (C) 2010 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据